Clinical and Economic Impact of Expanded TPMT Testing to Prevent Thiopurine‐Induced Myelosuppression in Australia: A Budget Impact Analysis

ABSTRACT Testing thiopurine methyltransferase (TPMT) enzyme activity or genotype prior to thiopurine prescribing is recommended to reduce the risk of moderate to severe—and potentially fatal—myelosuppression in poor or intermediate TPMT metabolizers. Despite this, only about one‐third of individuals...

Descripció completa

Dades bibliogràfiques

Autors principals:	Bella D. Ianni, Mohammad Afshar Ali, Chin Hang Yiu, Edwin C. K. Tan, Christine Y. Lu
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2026-02-01
Col·lecció:	Clinical and Translational Science
Matèries:	healthcare costs pharmacogenetic testing pharmacogenetics pharmacogenomics PLIDA precision medicine
Accés en línia:	https://doi.org/10.1111/cts.70389
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!